Applied Genetic Technologies Corporation (NASDAQ:AGTC) tinted gains of +3.23% (+0.17 points) to US$5.6. The volume of 0.06 Million shares climbed down over an trading activity of 88.99 Million shares. EPS ratio determined by looking at last 12 month figures is -0.7. Over the same time span, the stock marked US$6.05 as its best level and the lowest price reached was US$3.25. The corporation has a market cap of US$99.29 Million.
Applied Genetic Technologies Corporation (NASDAQ:AGTC)’s earnings per share has been growing at a 16.5 percent rate over the past 5 year when average revenue increase was noted as 105.3 percent. The return on equity ratio or ROE stands at 0 percent while most common profitability ratio return on investment (ROI) was -0.4 percent. The company’s institutional ownership is monitored at 59.9 percent. The company’s net profit margin has achieved the current level of 0 percent and possesses 0 percent gross margin.
Daily Analyst Recommendations
A number of key analysts, polled by FactSet, shared their views about the current stock momentum. The forecast of 1 surveyed investment analysts covering the stock advises investors to Buy stake in the company. At present, 0 analysts call it Sell, while 2 think it is Hold. Recently, analysts have updated the overall rating to 2.17. 3 analysts recommended Overweight these shares while 0 recommended Underweight, according to FactSet data.
Revance Therapeutics, Inc. (NASDAQ:RVNC) is worth US$1.05 Billion and has recently risen 3.22% to US$30.45. The latest exchange of 0.25 Million shares is below its average trading activity of 327.47 Million shares. The day began at US$0 but the price moved to US$0 at one point during the trading and finally capitulating to a session high of US$0. The stock tapped a 52-week high of US$37.45 while the mean 12-month price target for the shares is US$48.78.
Currently, the stock carries a price to earnings ratio of 0, a price to book ratio of 4.63, and a price to sales ratio of 2636.97. For the past 5 years, the company’s revenue has grown -18.2%, while the company’s earnings per share has grown -4.1%. With an institutional ownership near 98.1%, it carries an earnings per share ratio of -4.03.
Inside Look At Analysts Reviews
Latest analyst recommendations could offer little help to investors. The stock is a Buy among 1 brokerage firms polled by Factset Research. At present, 1 analysts recommended Holding these shares while 0 recommended sell, according to FactSet data. 0 analysts call it Underweight, while 9 think it is Overweight. Recently, investment analysts covering the stock have updated the mean rating to 2.